Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

Heather G Jørgensen, Elaine K Allan, Joanne C Mountford, Linda Richmond, Simon Harrison, Moira A Elliott, Tessa L Holyoake

Research output: Contribution to journal › Article

14 Citations (Scopus)

Abstract

In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.
Original languageEnglish
Pages (from-to)1140-6
Number of pages7
JournalExperimental Hematology
Volume33
Issue number10
DOIs
Publication statusPublished - 2005

Fingerprint

Bryostatins
Myeloid Progenitor Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell Cycle
Apoptosis
Protein Kinase C
Imatinib Mesylate
In Vitro Techniques

Keywords

  • antigens
  • antineoplastic agents
  • apoptosis
  • bryostatins
  • drug antagonism
  • hematopoietic stem cells
  • leukemia
  • macrolides
  • piperazines
  • protein kinase C
  • pyrimidines

Cite this

Jørgensen, H. G., Allan, E. K., Mountford, J. C., Richmond, L., Harrison, S., Elliott, M. A., & Holyoake, T. L. (2005). Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology , 33(10), 1140-6. https://doi.org/10.1016/j.exphem.2005.05.020
Jørgensen, Heather G ; Allan, Elaine K ; Mountford, Joanne C ; Richmond, Linda ; Harrison, Simon ; Elliott, Moira A ; Holyoake, Tessa L. / Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. In: Experimental Hematology . 2005 ; Vol. 33, No. 10. pp. 1140-6.
@article{d61614c95cdc40758d4d8e4c1b6b9b72,
title = "Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate",
abstract = "In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.",
keywords = "antigens, antineoplastic agents, apoptosis, bryostatins, drug antagonism, hematopoietic stem cells, leukemia, macrolides, piperazines, protein kinase C, pyrimidines",
author = "J{\o}rgensen, {Heather G} and Allan, {Elaine K} and Mountford, {Joanne C} and Linda Richmond and Simon Harrison and Elliott, {Moira A} and Holyoake, {Tessa L}",
year = "2005",
doi = "10.1016/j.exphem.2005.05.020",
language = "English",
volume = "33",
pages = "1140--6",
journal = "Experimental Hematology",
issn = "0301-472X",
number = "10",

}

Jørgensen, HG, Allan, EK, Mountford, JC, Richmond, L, Harrison, S, Elliott, MA & Holyoake, TL 2005, 'Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate', Experimental Hematology , vol. 33, no. 10, pp. 1140-6. https://doi.org/10.1016/j.exphem.2005.05.020

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. / Jørgensen, Heather G; Allan, Elaine K; Mountford, Joanne C; Richmond, Linda; Harrison, Simon; Elliott, Moira A; Holyoake, Tessa L.

In: Experimental Hematology , Vol. 33, No. 10, 2005, p. 1140-6.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

AU - Jørgensen, Heather G

AU - Allan, Elaine K

AU - Mountford, Joanne C

AU - Richmond, Linda

AU - Harrison, Simon

AU - Elliott, Moira A

AU - Holyoake, Tessa L

PY - 2005

Y1 - 2005

N2 - In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.

AB - In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.

KW - antigens

KW - antineoplastic agents

KW - apoptosis

KW - bryostatins

KW - drug antagonism

KW - hematopoietic stem cells

KW - leukemia

KW - macrolides

KW - piperazines

KW - protein kinase C

KW - pyrimidines

U2 - 10.1016/j.exphem.2005.05.020

DO - 10.1016/j.exphem.2005.05.020

M3 - Article

C2 - 16219536

VL - 33

SP - 1140

EP - 1146

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 10

ER -

Jørgensen HG, Allan EK, Mountford JC, Richmond L, Harrison S, Elliott MA et al. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology . 2005;33(10):1140-6. https://doi.org/10.1016/j.exphem.2005.05.020

Access to Document